Reference Interval:
By report
| Test Number
| Components
| Reference Interval
| | | Alpha Fetoprotein Total
| 0-15 ng/mL
| | | Alpha Fetoprotein L3 Percent
| 0-9.9 percent
|
|
| Interpretive Data: |
The µTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably. The AFP L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Patients with elevated serum AFP-L3 percent should be more intensely evaluated for evidence of hepatocellular carcinoma since elevated values have been shown to be associated with a seven-fold increase in the risk for developing hepatocellular carcinoma within 21 months. For pregnant females, the result is not interpretable as a tumor marker.
|
| CPT Code(s): |
82107
|
Cross References: |
AFP (Liver Cancer) (Alpha Fetoprotein, Total and L3 Percent), AFP-L3% (Alpha Fetoprotein, Total and L3 Percent), Alpha Fetoprotein (Liver Cancer) (Alpha Fetoprotein, Total and L3 Percent), Alpha Fetoprotein, Total and L3 Percent (Alpha Fetoprotein, Total and L3 Percent), Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum (Alpha Fetoprotein, Total and L3 Percent)
, Hepatocellular Carcinoma AFP (Alpha Fetoprotein, Total and L3 Percent) |
![[ image for: Additional Technical Information]](icon_386.jpg){kind=icon}